Alvimopan usage increasing following radical cystectomy

Joshua D. Belle, Aydin Pooli, Dmitry Oleynikov, Christopher M. Deibert

Research output: Contribution to journalArticle

Abstract

Purpose: Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC. Methods: The Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected. Results: 7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4%) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59%. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53% vs 19.23%, p = 0.027). Conclusion: This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.

Original languageEnglish (US)
Pages (from-to)1151-1155
Number of pages5
JournalWorld Journal of Urology
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

alvimopan
Cystectomy
Length of Stay
Morbidity
Colorectal Surgery
Narcotic Antagonists
Ileus

Keywords

  • Alvimopan
  • Bladder cancer
  • Cystectomy
  • Ileus
  • Vizient

ASJC Scopus subject areas

  • Urology

Cite this

Alvimopan usage increasing following radical cystectomy. / Belle, Joshua D.; Pooli, Aydin; Oleynikov, Dmitry; Deibert, Christopher M.

In: World Journal of Urology, Vol. 37, No. 6, 01.06.2019, p. 1151-1155.

Research output: Contribution to journalArticle

Belle, Joshua D. ; Pooli, Aydin ; Oleynikov, Dmitry ; Deibert, Christopher M. / Alvimopan usage increasing following radical cystectomy. In: World Journal of Urology. 2019 ; Vol. 37, No. 6. pp. 1151-1155.
@article{d7f728e9125d4876b5261f8381186ef2,
title = "Alvimopan usage increasing following radical cystectomy",
abstract = "Purpose: Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC. Methods: The Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected. Results: 7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4{\%}) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59{\%}. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53{\%} vs 19.23{\%}, p = 0.027). Conclusion: This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.",
keywords = "Alvimopan, Bladder cancer, Cystectomy, Ileus, Vizient",
author = "Belle, {Joshua D.} and Aydin Pooli and Dmitry Oleynikov and Deibert, {Christopher M.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s00345-018-2476-3",
language = "English (US)",
volume = "37",
pages = "1151--1155",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Alvimopan usage increasing following radical cystectomy

AU - Belle, Joshua D.

AU - Pooli, Aydin

AU - Oleynikov, Dmitry

AU - Deibert, Christopher M.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC. Methods: The Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected. Results: 7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4%) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59%. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53% vs 19.23%, p = 0.027). Conclusion: This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.

AB - Purpose: Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC. Methods: The Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected. Results: 7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4%) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59%. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53% vs 19.23%, p = 0.027). Conclusion: This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.

KW - Alvimopan

KW - Bladder cancer

KW - Cystectomy

KW - Ileus

KW - Vizient

UR - http://www.scopus.com/inward/record.url?scp=85053046946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053046946&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2476-3

DO - 10.1007/s00345-018-2476-3

M3 - Article

C2 - 30196313

AN - SCOPUS:85053046946

VL - 37

SP - 1151

EP - 1155

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 6

ER -